FDA ap­proves BeiGene's Brukin­sa in rare blood can­cer amid com­pa­ny's US ex­pan­sion plans

BeiGene has been any­thing but shy about its US ex­pan­sion plans cen­tered around blood can­cer drug Brukin­sa. To see those plans through, BeiGene will have to go right at Ab­b­Vie and J&J’s Im­bru­vi­ca, and Brukin­sa now has one more ar­row in its quiver as part of that bat­tle.

The FDA on Wednes­day ap­proved BTK in­hibitor Brukin­sa to treat Walden­ström’s macroglob­u­line­mia, a rare form of lym­phoma, af­ter the drug aced a head-to-head show­down with Im­bru­vi­ca, the on­ly oth­er drug ap­proved for that dis­ease, BeiGene said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER